JUL 16, 2020 4:36 AM PDT

A New Drug Candidate to Combat Cardiac Fibrosis

WRITTEN BY: Jasper Cantrell

Medicine is undoubtedly reaching a golden age, as researchers expand diagnostic and therapeutic tools like never before. Studies reveal new biomarkers every year. These biomarkers act as markers of disease progression, as well as starting points for further therapeutic investigations. Cancer is what usually gets the most attention, but cardiovascular disease is easily the next on the list.

Heart failure is a cardiac condition and one of the leading reasons for hospitalization worldwide. One of its primary causes is a condition called cardiac fibrosis. Cardiac Fibrosis is when cardiac fibroblasts accumulate in the heart. These fibroblasts form a thick layer of tissue around the heart and make it harder for the heart to beat. Researchers are investigating biomarkers to follow this process, and maybe even prevent it before it causes heart failure.

One team from the Universite de Paris in France had previously identified one such biomarker candidate. Their study had found that twenty-two percent of the cardiac fibroblasts in a mouse model stemmed from the expression of the protein PW1. PW1 is a genetic factor that transformed stem cells into cardiac fibroblasts, which then began to accumulate in the hearts of the mice and cause heart failure. A new study sought to elaborate more on this and identify how PW1 might work.

They reasoned that PW1 was involved in genetic expression, and therefore needed a receptor protein that would need to be activated. The team began by identifying receptors on the outside of the cell proteomics to measure proteins, and transcriptomics to measure genetic activity. This process revealed five prime candidates found in PW1+ cardiac cells. Of these, only αV-integrin (CD51) was unique to PW1+ cells.

CD51 is a cell receptor involved in cell-cell interactions and associated with the differentiation of stem cells. Further study showed that it was not only upregulated in PW1+ cells, but a particular complex of two aV-integrin variants was unique to PW1+ fibroblasts.

The team then used an inhibitor of CD51 to investigate its role in heart failure. Mouse models revealed that the inhibitor significantly reduced fatalities due to heart attacks. CD51 inhibition had reduced the accumulation of cardiac fibroblasts in the hearts of the mice. In other words, it had suppressed cardiac fibrosis.

This study provides a strong candidate for a new cardiac fibrosis biomarker. The team showed that in mice, inhibition of CD51 prevented PW1 dependent transformation of stem cells into cardiac fibroblasts. This inhibition significantly reduced cardiac fibrosis progression, which led to increased survival post-heart attack in mouse models.

The team concludes, “Overall, these data identify cardiac PW1+ cells as a source of cardiac fibrosis in response to ischemic injury via αV-integrin and suggest that the pharmacological targeting of αV-integrin may offer clinical benefits in the treatment of cardiac ischemia.” They note that there are already anti-CD51 drugs in clinical trials targeted for cancer and hope they may be tested for cardiac fibrosis therapy as well.

Sources: Nature Scientific Reports, STBHFoundation

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAR 02, 2021
Cardiology
Creating a Light Switch in the Heart to Regulate Heart Rate
MAR 02, 2021
Creating a Light Switch in the Heart to Regulate Heart Rate
Often when it is dark, we go for a flashlight or our phone to see where we are going. What if I told you that is much th ...
APR 06, 2021
Cardiology
In 2020, Deaths in the US Were Over 20% Higher Than Typical Years
APR 06, 2021
In 2020, Deaths in the US Were Over 20% Higher Than Typical Years
Researchers have begun to analyze the impact of the pandemic, and their work has shown that long COVID-19 surges in the ...
APR 20, 2021
Cardiology
Does Impaired Glucose Tolerance Increase Heart Damage After a Stroke?
APR 20, 2021
Does Impaired Glucose Tolerance Increase Heart Damage After a Stroke?
Diabetes is a looming threat to the world’s healthcare systems. Diagnoses of its precursors, impaired glucose tole ...
JUN 26, 2021
Space & Astronomy
Cardiac Atrophy Findings May Aid Astronauts in Long Space Flights
JUN 26, 2021
Cardiac Atrophy Findings May Aid Astronauts in Long Space Flights
Researchers led by Cincinnati Children’s Hospital Medical Center have discovered the molecular process behind a da ...
JUL 05, 2021
Cardiology
Breathing Exercise Seems as Beneficial as Medication or Walking
JUL 05, 2021
Breathing Exercise Seems as Beneficial as Medication or Walking
Heart disease is a major killer, and high blood pressure is a major risk factor. About 65 percent of American adults hav ...
AUG 12, 2021
Cardiology
Benefits of Plant-Based Diets Demonstrated in Long-Term Study
AUG 12, 2021
Benefits of Plant-Based Diets Demonstrated in Long-Term Study
New research has confirmed studies that have indicated how beneficial a diet rich in nutritious foods like fruits, veget ...
Loading Comments...